Inhibitor Therapeutics provides update on itraconazole PK study; plans global patent filing for amorphous formulation

Inhibitor Therapeutics, Inc.

Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.
Study is the final clinical study before NDA submission to FDA under 505(b)(2) pathway for Gorlin Syndrome BCCNS.
New global patent application planned for proprietary amorphous itraconazole formulation; owned by Inhibitor with no royalty obligations.
Amorphous formulation aims to enhance solubility and absorption vs. crystalline itraconazole to address variable exposure.
Study conducted with Avior Bio in Malaysia; advancing on planned timelines and budget.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.